コーパス検索結果 (left1)
通し番号をクリックするとPubMedの該当ページを表示します
1 SP-A alone had no effect upon inflammatory mediators in
2 SP-A also decreased TNF-alpha and CXCL10 secretion by ex
3 SP-A also reduces the phosphorylation of TLR signaling p
4 SP-A and SP-B(N) were able to interact in solution (Kd =
5 SP-A augmented CR3-mediated phagocytosis in a manner tha
6 SP-A can also bind the Mp membrane protein, MPN372.
7 SP-A decreases the phosphorylation of IkappaBalpha, a ke
8 SP-A functions as an important mediator in resolving tis
9 SP-A gene expression is developmentally regulated in fet
10 SP-A has a bacteriostatic effect on Mycoplasma pneumonia
11 SP-A has been proposed as a fetally produced signal for
12 SP-A inhibited LPS induced IkappaB-alpha degradation in
13 SP-A interaction with the EGFR signaling pathway appears
14 SP-A plays an important role in the lung during bacteria
15 SP-A prevented the invasion of AEC by alginate-producing
16 SP-A significantly suppressed TLR ligand-induced express
17 SP-A(-/-) alloBMT or SP-A-sufficient recipient mice that
18 SP-A(-/-) mice were challenged in allergen models, and e
19 SP-A(-/-)alloBMT mice also had increased colon expressio
20 SP-A, as well as the enzyme lysophosphatidylcholine acyl
21 SP-A-deficient mice are more susceptible than wild-type
22 SP-A/SP-B(N)-treated infected mice showed significant re
24 collectins surfactant-associated protein A (SP-A) and SP-D are components of innate immunity that ar
27 The identification of surfactant protein A (SP-A) as an important innate immune factor of the lungs,
30 rted that mice lacking surfactant protein A (SP-A) have increased airway hyperresponsiveness (AHR) du
32 role for the collectin surfactant protein A (SP-A) in regulating the development of GVHD after alloge
33 da with lung collectin surfactant protein A (SP-A) increased bacterial association and intracellular
45 The lung collectin, surfactant protein A (SP-A), has emerged as an important innate immune determi
49 -1 and SRC-2) regulate surfactant protein-A (SP-A) and platelet-activating factor (PAF) expression, w
50 ports demonstrate that surfactant protein-A (SP-A) binds live M. pneumoniae and mycoplasma membrane f
52 his defense mechanism, surfactant protein-A (SP-A), exerts multifunctional roles in mediating host re
53 -type lectins, such as surfactant protein-A (SP-A), SP-D, and mannose-binding lectin (MBL); phagocyte
56 pulmonary collectins--surfactant proteins A (SP-A) and D (SP-D)--play important roles in innate host
57 miting available molecular information about SP-A interactions with microbial surface components.
60 teins acted synergistically in vitro against SP-A- and SP-B(N)-resistant capsulated Klebsiella pneumo
73 examined the effect of interactions between SP-A and the pathogenic TLR agonists lipopolysaccharide
75 mice that have undergone an allogeneic BMT [SP-A(-/-)alloBMT] or SP-A-sufficient recipient mice that
77 homeostasis, we generated mice lacking both SP-A and MCs (SP-A(-/-)Kit(W-sh/W-sh)) and infected them
79 ly cleared in the lungs of wild-type mice by SP-A-mediated membrane permeabilization, and not by opso
80 tant was more susceptible to opsonization by SP-A and by other pulmonary and circulating opsonins, SP
82 hese structurally related defense collagens, SP-A and C1q, and the expression of their receptor, myos
89 adequate amounts of exoproteases to degrade SP-A in vitro and in vivo, leading to its preferential c
95 ly be restored after administering exogenous SP-A containing both SP-A1 and SP-A2 into the lungs of S
99 ther the mother or the pup or oral exogenous SP-A significantly reduced newborn mortality associated
100 Importantly, reconstitution with exogenous SP-A into the lungs of SP-A(-/-) mice stimulated with a
102 increase on extended culture with exogenous SP-A, providing a key mechanism for the maintenance and
104 nd/or more effectively by CHO cell-expressed SP-A variants than by insect-cell expressed SP-A variant
109 membrane protein OprH as a novel ligand for SP-A on P. aeruginosa The last-available (late) isolates
111 These findings suggest a protective role for SP-A in limiting MMF-stimulated mucin production that oc
113 These data identify a critical role for SP-A in modulating the lung inflammatory response by reg
114 opment of GI GVHD and establishes a role for SP-A in regulating the immune response in the GI tract.
120 ndergone an allogeneic BMT) or C57BL/6 (H2b; SP-A-deficient recipient mice that have undergone a syng
121 deficient mice on a C57BL/6 background (H2b; SP-A(-/-)) mice underwent allogeneic or syngeneic BMT wi
122 c BMT with cells from either C3HeB/FeJ (H2k; SP-A-deficient recipient mice that have undergone an all
123 y to undergo conformational changes may help SP-A adapt to different ligand classes, including microb
126 provides a signal for parturition; however, SP-A-deficient mice have only a relatively modest delay
127 cant differences in lung pathology; however, SP-A(-/-)alloBMT mice developed marked features of GI GV
129 se questions, we studied the effect of human SP-A on rat and human aMvarphis stimulated with IFN-gamm
130 y in human asthmatic patients and that human SP-A inhibits M pneumoniae-stimulated transcription and
131 r the multiple functions attributed to human SP-A, as well as the regulatory complexity of its expres
132 n an OVA model of allergic hypersensitivity, SP-A(-/-) mice had greater eosinophilia, Th2-associated
135 introduced concurrently with MASP binding in SP-A but is uncontrolled and occurs even in the absence
136 udies, we demonstrate that mice deficient in SP-A that have undergone an allogeneic BMT have a greate
142 tured HFL type II cells blocked cAMP-induced SP-A expression and accumulation of surfactant-containin
145 tory in the lung during bacterial infection, SP-A regulation of secretory leukoprotease inhibitor (SL
148 om patients with CF bound significantly less SP-A than their respective first-available (early) isola
149 and type II alveolar epithelial cells marker SP-A, indicating the potential importance of CDC42 in th
151 we generated mice lacking both SP-A and MCs (SP-A(-/-)Kit(W-sh/W-sh)) and infected them with M pneumo
153 exogenous SP-A delivered by mouth to newborn SP-A null pups with SP-A null mothers improved newborn s
155 n production to MMF occurs in the absence of SP-A and is not dependent upon neutrophil recruitment.
156 In this article, we show that the absence of SP-A during M. pneumoniae infection leads to increased n
160 livery model, intrauterine administration of SP-A significantly inhibited preterm delivery, suppresse
162 inflammatory agents and that the binding of SP-A to IFN-gamma abrogates IFN-gamma effects on human m
164 h endoglycosidase H abrogates the binding of SP-A, indicating that the high mannose structures on gp1
166 urse of evolution, the genetic complexity of SP-A has increased, particularly in the regulatory regio
169 on of exoproteases and limits degradation of SP-A, thereby conferring susceptibility to this major pu
170 neck and carbohydrate recognition domain of SP-A with d-mannose, D-alpha-methylmannose, and glycerol
175 ortant role in the structure and function of SP-A and is a major factor for the differences between S
179 observed that the developmental induction of SP-A was associated with increased recruitment of TTF-1,
182 -R210(L) mediates recognition and killing of SP-A-opsonized S. aureus in vivo, coordinating inflammat
183 is (IPF) often have elevated serum levels of SP-A and SP-D, although their role in the disease is not
186 polysaccharide is surface-exposed, levels of SP-A may be crucial to modulate the interaction of P. ae
190 tution with exogenous SP-A into the lungs of SP-A(-/-) mice stimulated with a strong signal also resu
192 family members as TTF-1-driven mediators of SP-A expression and type II cell differentiation through
193 proliferation is enhanced in the presence of SP-A at low SoS imparted by exogenous mitogens, specific
196 significant complexity of the regulation of SP-A expression at different levels, including transcrip
199 In this study, we investigated the role of SP-A during acute phase pulmonary infection with Mp usin
205 hypoxia, which inhibits cAMP stimulation of SP-A, markedly increased Suv39h1 and Suv39h2 binding to
206 d by N-glycanase or collagenase treatment of SP-A, implicating the N-linked sugar and collagen-like d
208 ire of single-amino acid genetic variants of SP-A that may be associated with lung disease, and our f
212 gone an allogeneic BMT [SP-A(-/-)alloBMT] or SP-A-sufficient recipient mice that have undergone an al
213 mice that have undergone a syngeneic BMT or SP-A-sufficient recipient mice that have undergone a syn
215 lonal antibodies to CKAP4/P63, the principal SP-A-binding receptor on AEC, or inhibition of its expre
217 binding into a pulmonary surfactant protein (SP-A), which has the same domain structure and architect
218 expression of the major surfactant protein, SP-A, in mid-gestation human fetal lung (HFL) are induce
219 FTPA) encoding the major surfactant protein, SP-A, in midgestation human fetal lung (HFL) is dramatic
220 rgen-challenged SP-A(-/-) mice that received SP-A therapy had significantly less tissue eosinophilia
222 e does not involve an overt lack of secreted SP-A but instead involves an increase in ER stress of re
223 timulated with LPS and IFN-gamma separately, SP-A inhibited both LPS-induced signaling and IFN-gamma-
225 ox-1 (HMGB-1) abrogated this effect and that SP-A inhibits HMGB-1 release from immune cells suggest t
230 with dendritic cells (DCs) demonstrate that SP-A enhances the binding of gp120 to DCs, the uptake of
231 kinetic suppression assays demonstrate that SP-A enhances the frequency of functional Foxp3(+) Tregs
233 he results of these studies demonstrate that SP-A protects against the development of GI GVHD and est
237 , these findings support the hypothesis that SP-A affects T cell immune function by the induction of
242 capture of the HIV viral lysate reveals that SP-A targets the envelope glycoprotein of HIV (gp120), w
245 However, previous studies have shown that SP-A also aids in the formation and biophysical properti
247 Collectively, these results suggest that SP-A acts as a dual modulator of HIV infection by protec
248 with CD4 and mAbs F105 and b12 suggest that SP-A inhibits infectivity by occlusion of the CD4-bindin
249 MGB-1 release from immune cells suggest that SP-A inhibits M. pneumoniae-induced DC maturation by reg
250 findings in this study strongly suggest that SP-A signals amniotic anti-inflammatory response via AF
252 Finally, we report for the first time that SP-A decreases the phosphorylation of Akt, a major cell
255 (+) DCs and Foxp3(+) T regulatory cells, the SP-A(-/-) mice had elevated proportions of CD4(+) activa
256 cell pools demonstrated that cells from the SP-A(-/-) OVA mice had the greatest proliferative and IL
258 ult of the conformational change is that the SP-A lectin site and the surrounding loop region become
262 Intratracheal administration of SP-A to SP-A(-/-) mice enhanced SLPI protein expression and anti
264 n of (IFN-gamma + LPS) stimulation is due to SP-A attenuation of both inflammatory agents and that th
267 lates were at least 2-fold more resistant to SP-A-mediated killing by human macrophages than their re
270 G231V mutation have similar levels of total SP-A as normal family members, which suggests that the m
272 not secreted into the medium with wild-type SP-A isoforms, form fewer intracellular dimer and trimer
273 -A and SP-D in neonatal immunity, wild-type, SP-A null, and SP-D null mice were bred in a bacterium-l
275 rison of these complexes with the unliganded SP-A neck and carbohydrate recognition domain revealed a
278 g an acute pneumonia model in SP-A+/+ versus SP-A-/- mice, the O-glycosylation-deficient DeltatfpO mu
286 xact role of SP-A and the mechanism by which SP-A affects IFN-gamma-induced activation of alveolar ma
289 SP-D did not affect newborn survival, while SP-A produced by either the mother or the pup or oral ex
295 ysis of human amnion explants incubated with SP-A revealed a molecular signature of inhibited cytokin
297 reatment of K. pneumoniae-infected mice with SP-A and SP-B(N) conferred more protection against K. pn
298 ered by mouth to newborn SP-A null pups with SP-A null mothers improved newborn survival in the corn
299 ly, we found that therapeutic treatment with SP-A and SP-B(N) 6 or 24 h after bacterial challenge con
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。